课题基金 / 基金详情

IGF::OT::IGF FORMULATION DEVELOPMENT AND EVALUATION STUDIES OF METHOTREXATE, NEVIRAPINE, SUTEZOLID, LEVOFLOXACIN, AND RUXOLITNIB

IGF::OT::IGF FORMULATION DEVELOPMENT AND EVALUATION STUDIES OF METHOTREXATE, NEVIRAPINE, SUTEZOLID, LEVOFLOXACIN, AND RUXOLITNIB
甲氨蝶呤、奈韦拉平、舒替唑胺、左氧氟沙星和鲁索利尼的 IGF::OT::IGF 制剂开发和评价研究
批准号:
8938940
负责人:
KATHRYN BAUGHMAN
金额:
$12.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-13 至 2015-08-12

项目摘要

项目成果

KATHRYN BAUGHMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Division of Acquired Immunodeficiency Syndromes (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), maintains a portfolio of contracts to support the development of (1) therapies for HIV infection and its complications and coinfections, and (2) microbicides for preventing the sexual transmission of HIV. Services provided under this contracts assist investigators in academic settings and small pharmaceutical firms in filling specific gaps in their drug development plan as they advance their product towards clinical investigation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Development Services for AIDS Therapeutics
  • 批准号:
    9932231
  • 项目类别:
  • 资助金额:
    $24.53万
  • 财政年份:
    2019
  • 负责人:
    KATHRYN BAUGHMAN
  • 依托单位:
BIOLOGICAL TESTING FACILITY - MAINTENANCE OF EXISTING NON-HUMAN PRIMATE COLONY
  • 批准号:
    9922696
  • 项目类别:
  • 资助金额:
    $31.59万
  • 财政年份:
    2018
  • 负责人:
    KATHRYN BAUGHMAN
  • 依托单位:
BIOLOGICAL TESTING FACILITY - MAINTENANCE OF EXISTING NON-HUMAN PRIMATE COLONY
  • 批准号:
    9774893
  • 项目类别:
  • 资助金额:
    $104.2万
  • 财政年份:
    2018
  • 负责人:
    KATHRYN BAUGHMAN
  • 依托单位:
IGF::OT::IGF:CONTRACT ADMINISTRATION - PERIOD OF PERFORMANCE 9/13/2016-9/12/2017
  • 批准号:
    9374281
  • 项目类别:
  • 资助金额:
    $3.24万
  • 财政年份:
    2016
  • 负责人:
    KATHRYN BAUGHMAN
  • 依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究